Tract Embolization versus No Embolization after CT-Guided Lung Biopsy: A Systematic Review and Meta-Analysis.

J Vasc Interv RadiolMay 15, 2026 (epub)
Clinical ResearchPulmonologyRadiology (Diagnostic)

Bernard Campos Araruna Giancristoforo, Davi Barbosa, Maria Clara Merighi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness of tract embolization (TE) in preventing pneumothorax and chest tube placement after CT-guided lung biopsy. Analyzing 26 studies with 10,689 patients, TE significantly reduced the risk of pneumothorax (RR, 0.59) and chest tube placement (RR, 0.47), indicating its potential as an effective adjunct to minimize complications.

Key findings

  • TE was associated with a lower risk of pneumothorax (RR, 0.59; 95% CI, 0.53-0.65).
  • TE reduced chest tube placement rates (RR, 0.47; 95% CI, 0.37-0.58).
  • Blood patch and gelatin sponge both showed significant reductions in pneumothorax and chest tube placement.

Why it matters

Understanding the benefits of tract embolization can help clinicians minimize complications associated with CT-guided lung biopsies, potentially improving patient outcomes and reducing the need for additional interventions.

Source

PubMed · PMID 42142830

Published in J Vasc Interv Radiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pulmonology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.